Login to Your Account

Mirati Turns to Markets for $56.9M Raise

By Catherine Shaffer
Staff Writer

Friday, October 25, 2013

A new underwritten public offering of about 3.25 million shares of common stock by Mirati Therapeutics Inc. will support the company’s Phase I/II push for cancer candidates MGCD265 and MGCD516, as well as an open-label, dose-confirmation trial of its late-stage candidate mocetinostat. Mirati will price the stock at $17.50 per share, and expects gross proceeds of about $56.9 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription